PMC4680105_01
MRI of the neck revealing an anterior tongue mass.
CRIOT2015-242135.001.jpg
PMC4680105_01_CRIOT2015-242135.001.jpg
fig1
MRI of the neck revealed a mass involving the anterior two-thirds of the right tongue with irregular margins and ipsilateral right jugulodigastric lymphadenopathy (Figure 1).
H&E stain showing poorly differentiated adenocarcinoma.
CRIOT2015-242135.002.jpg
PMC4680105_01_CRIOT2015-242135.002.jpg
fig2
Punch biopsies of the tongue mass revealed poorly differentiated adenocarcinoma positive for cytokeratin 20, cytokeratin 5/6, P16, P63, CDx-2, Villin, and polyclonal CEA (Figures 2   -6).
IHC stain showing cytokeratin 20 (a and b) and CDx-2 (c) positivity, markers normally associated with gastrointestinal malignancies.
CRIOT2015-242135.003.jpg
PMC4680105_01_CRIOT2015-242135.003.jpg
fig3
Punch biopsies of the tongue mass revealed poorly differentiated adenocarcinoma positive for cytokeratin 20, cytokeratin 5/6, P16, P63, CDx-2, Villin, and polyclonal CEA (Figures 2   -6).
IHC stain positive for CK 5/6.
CRIOT2015-242135.004.jpg
PMC4680105_01_CRIOT2015-242135.004.jpg
fig4
Punch biopsies of the tongue mass revealed poorly differentiated adenocarcinoma positive for cytokeratin 20, cytokeratin 5/6, P16, P63, CDx-2, Villin, and polyclonal CEA (Figures 2   -6).
IHC stain positive for polyclonal CEA.
CRIOT2015-242135.005.jpg
PMC4680105_01_CRIOT2015-242135.005.jpg
fig5
Punch biopsies of the tongue mass revealed poorly differentiated adenocarcinoma positive for cytokeratin 20, cytokeratin 5/6, P16, P63, CDx-2, Villin, and polyclonal CEA (Figures 2   -6).
IHC stain positive for P63.
CRIOT2015-242135.006.jpg
PMC4680105_01_CRIOT2015-242135.006.jpg
fig6
Punch biopsies of the tongue mass revealed poorly differentiated adenocarcinoma positive for cytokeratin 20, cytokeratin 5/6, P16, P63, CDx-2, Villin, and polyclonal CEA (Figures 2   -6).
PET scan showing hypermetabolic activity in the tongue and neck.
CRIOT2015-242135.007.jpg
PMC4680105_01_CRIOT2015-242135.007.jpg
fig7
PET scan revealed hypermetabolic activity in the tongue and neck consistent with metastatic disease (Figures 7(a) and 7(b)).